BOSTON, Oct. 26 /PRNewswire/ -- Scimitar Equity Research, Inc. (Scimitar) issues a review of StatSure Diagnostic Systems, Inc. (OTC Bulletin Board: SSUR), entitled, "Opportunity Unfolds for Investors Seeking to Participate In a Proprietary Point-of-Care Firm".
This review is available at our website: http://www.scimitarequity.com.
StatSure Diagnostic Systems, Inc. is engaged in the development, manufacture and marketing of rapid immunoassay tests for the detection of sexually transmitted and other infectious diseases; in addition, the Company has developed and is marketing a product line of patented, oral- fluid collection devices. The Company's proprietary platforms provide significant customer benefits and competitive advantages as compared to similar products that are currently available. Improved accuracy, operator convenience, and reduced risk of infection from collecting and handling specimens, have been engineered into SDS products. All of the company's diagnostic tests are based on the same easy-to-use technology platform, thus facilitating the development of future products. Certain of these products are sold in the United States as well as internationally to various distributors for use in clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations. Please visit our website at http://www.StatSure.com
ABOUT Scimitar Equity Research, Inc.
Scimitar Equity Research, Inc. provides sponsored equity research of
the health sciences industry for the institutional and investment
communities. We certify that all the views expressed in this review,
accurately reflect our personal views about SSUR.OB (OTC Bulletin Board)
and its or their securities. No part of our compensation was, is, or will
be, directly or indirectly, related to the specific recommendations
|SOURCE Scimitar Equity Research, Inc.|
Copyright©2007 PR Newswire.
All rights reserved